(VIANEWS) – Shares of MEDINCELL (CAC 40: MEDCL.PA) dropped by a staggering 20.61% in 10 sessions from €8.88 to €7.05 at 02:06 EST on Monday, after five successive sessions in a row of losses. CAC 40 is rising 0.45% to €7,414.85, after two successive sessions in a row of gains.
MEDINCELL’s last close was €7.05, 32.86% under its 52-week high of €10.50.
About MEDINCELL
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-0.97.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDINCELL’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
MEDINCELL’s stock is valued at €7.05 at 02:06 EST, way under its 52-week high of €10.50 and way higher than its 52-week low of €4.73.
Volume
Today’s last reported volume for MEDINCELL is 462954 which is 377.65% above its average volume of 63456.
More news about MEDINCELL (MEDCL.PA).
